The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]: a single technology appraisal

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]: a single technology appraisal
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Menarini Stemline UK Ltd on the clinical effectiveness and cost effectiveness of elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1mutation after at least one endocrine treatment. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the external assessment group (EAG) and to help inform this report.
National Institute for Health Research
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67

Maund, Emma, Takahashi, Marcia, Lord, Joanne and Shepherd, Jonathan (2025) Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]: a single technology appraisal National Institute for Health Research 157pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Menarini Stemline UK Ltd on the clinical effectiveness and cost effectiveness of elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1mutation after at least one endocrine treatment. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the external assessment group (EAG) and to help inform this report.

Text
Elacestrant EAG report - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

Published date: 5 February 2025
Related URLs:

Identifiers

Local EPrints ID: 504150
URI: http://eprints.soton.ac.uk/id/eprint/504150
PURE UUID: 628c5d87-8c64-4843-b20a-e27e3863dfb1
ORCID for Emma Maund: ORCID iD orcid.org/0000-0002-3998-6669
ORCID for Marcia Takahashi: ORCID iD orcid.org/0000-0002-6932-2660
ORCID for Joanne Lord: ORCID iD orcid.org/0000-0003-1086-1624
ORCID for Jonathan Shepherd: ORCID iD orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 28 Aug 2025 16:30
Last modified: 17 Oct 2025 02:10

Export record

Contributors

Author: Emma Maund ORCID iD
Author: Marcia Takahashi ORCID iD
Author: Joanne Lord ORCID iD
Author: Jonathan Shepherd ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×